Max Marchione(@maxmarchione):I overstated how interesting this kisspeptin study is. Four problems: 1) Only 32 men completed the trial (all diagnosed with HSDD, not ED) 2) The active treatment was a single 75-minute IV infusion which doesn't really tell us whether effects continue with repeated/long-term use 3) The primary endpoint was changes in brain activity, not better sex or erections or quality of life 4) The 56% was the difference in penile tumescence, not improvement in erectile function The study is a neat mechanistic proof-of-concept, but as evidence for kisspeptin being a serious ED drug, it's a bit of a dud.

2026.08.17 20:48

I overstated how interesting this kisspeptin study is. Four problems: 1) Only 32 men completed the trial (all diagnosed with HSDD, not ED) 2) The active treatment was a single 75-minute IV infusion which doesn't really tell us whether effects continue with repeated/long-term use 3) The primary endpoint was changes in brain activity, not better sex or erections or quality of life 4) The 56% was the difference in penile tumescence, not improvement in erectile function The study is a neat mechanistic proof-of-concept, but as evidence for kisspeptin being a serious ED drug, it's a bit of a dud.

Max Marchione@maxmarchione

2026.08.14 19:02

A peptide increased penile enlargement during sexual arousal by up to 56% vs placebo. Kisspeptin also changed activity across the brain’s sexual-processing network. This could be a replacement for the 300M ED drugs sold in the US every year.